About this trial
Acute myocardial infarction (AMI) initiates a complex myocardial repair process involving inflammation, fibroblast activation, and extracellular matrix remodeling, which may ultimately lead to adverse left ventricular remodeling and impaired cardiac function. Fibroblast activation protein (FAP)-targeted positron emission tomography (PET) enables noninvasive visualization of activated fibroblasts and may provide an early imaging biomarker of myocardial remodeling. This prospective single-center observational study aims to evaluate myocardial fibroblast activation using Ga-68 FAPI PET/MR performed approximately 10 ± 2 days after AMI and to investigate its association with subsequent left ventricular remodeling. Serial cardiac magnetic resonance (CMR) examinations will be performed at 3 and 6 months to assess changes in ventricular function and remodeling. The study will investigate whether early myocardial FAPI uptake is associated with subsequent structural and functional changes detected by CMR and evaluate the potential role of Ga-68 FAPI PET/MR as an imaging biomarker for post-infarction remodeling.
Eligibility criteria
Qualifiers
Age ≥18 years.
Diagnosis of acute myocardial infarction according to current guideline criteria.
Successful coronary revascularization when clinically indicated.
Ability to undergo FAPI PET/MR.
Disqualifiers
Contraindications to MRI (e.g., non-MR-compatible implanted devices, severe claustrophobia).
Pregnancy or breastfeeding.
Severe renal impairment precluding gadolinium administration (if contrast-enhanced MR is performed).
Inability to provide informed consent.
Trial design
Treatments tested in this trial
- 68Ga-FAPI-04 PET/MR